We aimed to elucidate the resistance mechanisms to ABCP further by conducting a scRNA‐seq analysis of EGFR‐TKI‐resistant NSCLC patients grouped into ABCP responders and nonresponders (Figure 1A). Here, ABCG2 is linked to non-small cell lung carcinoma.